Cancer research giants collaborate to present the CTRC-AACR San Antonio Breast Cancer...( SAN ANTONIO The Cancer Therapy & R...),Health
Navigation Links
Cancer research giants collaborate to present the CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/13/2007
SAN ANTONIO The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio and the American Association for Cancer Research (AACR) announced today a collaboration for the future of the San Antonio Breast Cancer Symposium (SABCS). The announcement came at the 30th Annual Charles A. Coltman Jr. San Antonio Breast Cancer Symposium, held at the Henry B. Gonzalez Convention Center in San Antonio. As a result of the collaboration, the symposium will be renamed the CTRC-AACR San Antonio Breast Cancer Symposium beginning in 2008. Complementing the clinical strengths of the highly regarded annual San Antonio Breast Cancer Symposium, the AACRs scientific prestige in basic, translational and clinical cancer research will create a unique and comprehensive scientific meeting that will advance breast cancer research for the benefit of patients.
The San Antonio Breast Cancer Symposium attracts academic and private physicians and researchers, as well as other health care professionals focused on curing breast cancer, to discuss and learn about new and late-breaking research including experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and pre-malignant breast disease, as well as new findings from clinical trials. A primary goal of the CTRC-AACR collaboration is to attract to the meeting more thought-leaders and high-quality proffered papers in basic and translational breast cancer research. Another key goal is to increase the participation of young investigators by providing superior education and training opportunities for the next generation of breast cancer researchers.
The driving force behind the collaboration is the shared mission of the partners to advance progress against breast cancer. By combining their respective strengths, the partnership will produce a scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translat
'/>"/>
| Contact: Staci Vernick Goldberg staci.goldberg@aacr.org 267-647-0616 American Association for Cancer Research Source:Eurekalert |
Related medicine news :
1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
(Date:12/3/2009)...than 1,500 Jobs Listed through APHA,s Public Healt...ire-USNewswire/ -- Today,s White House jobs summit... many professions, including public health. One pu...onnect job seekers to more than 1,500 jobs in the ...ttp://www.apha.org/about/careers/ is a full onlin...
(Date:12/3/2009)...stics play a major role in determining who succeed...lished in the November issue of the Journal of Ap...rsity of Minnesota psychology professor Deniz Ones...rough their seven-year medical school career, inve...e to learning and performance in general. , Duri...
(Date:12/3/2009)... 450 Deaths a day is still too many - stalled mom... Atlanta, GA, Geneva, New York,... The Measles Initiative announced today that measl...008, from an estimated 733 000 in 2000 to 164 000 ... of a resurgence in measles deaths if vaccination ...
(Date:12/3/2009)... Henninger,s creative staff caps off successful 2... work and 5 awards for post production services. ... -- The 13th Annual TIVA Peer Awards were presente...onal Press Club in Washington, D.C. last week. He...apped off a successful year for its creative team,...
(Date:12/3/2009)...tes: A Deeper Look Educates Americans About Thi... All Ages ,, DETROIT, Dec. 3 /PRNewswire-USNe...osed with diabetes every 21 seconds. On December 5...newest exhibit, Diabetes: A Deeper Look, to help... diabetes, diabetes treatment and the role insulin...
Breaking Medicine News(10 mins):Health News:Public Health Jobs Site Available to Help Meet Growing Demand 2Health News:Personality predicts success in medical school, says new study by U of Minnesota professor 2Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 2Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 3Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 4Health News:Henninger Media Services Wins 9 TIVA Peer Awards 2Health News:Henninger Media Services Wins 9 TIVA Peer Awards 3Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 2Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 3Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 4[0] Public Health Jobs Site Available to Help Meet Growing Demand[0] Personality predicts success in medical school, says new study by U of Minnesota professor[0] Global Measles Deaths Drop By 78%, But Resurgence Likely[0] Henninger Media Services Wins 9 TIVA Peer Awards[0] Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center
... MinuteClinic, the pioneer and largest provider o...ed that it has become a participating provider in ... of South Carolina. , , BlueCross, Preferred Blue...ss BlueShield of South Carolina is an independent ...
...Feb. 5 Palomar Medical Technologies, Inc. (Nasdaq...light-based systems for cosmetic treatments, today...r and year ended December 31, 2008. Revenues for ... were funded development revenues, and $1.25 milli...
...ISCO, Calif., Feb. 5 Rigel,Pharmaceuticals, Inc. ...wer, the,company,s chairman and chief executive of...at the 11th Annual BIO CEO & Investor Conferen...http://www.rigel.com . Please connect to Rigel,s w...
...b. 5 ATS Medical, Inc.,(Nasdaq: ATSI ), manufac...gery,products and services, announced today that t...A) has granted approval for commercialization of t..., (Logo: http://www.newscom.com/cgi-bin/prnh...
... Validation Study Affirms Highly Automated Ca...g Development , Rochester...chnologies, Inc., a leading innovator in advanced ... companies. The study validated the use of its Hig...
...rs from Boston Medical Center (BMC) and Boston Uni...process to minimize discharge failures. The Re-Eng...tilization within 30 days of discharge by over 30 ...ve hospitalizations is complicated by a post-disch...
Other Medicine News:Health News:MinuteClinic Becomes Participating Provider With Preferred Blue Network of BlueCross BlueShield of South Carolina 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 3Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 4Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 5Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 6Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 8Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 9Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 10Health News:ATS Medical Announces Australian Regulatory Approval for ATS 3f Aortic Bioprosthesis 2Health News:ATS Medical Announces Australian Regulatory Approval for ATS 3f Aortic Bioprosthesis 3Health News:iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies 2Health News:iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies 3Health News:Researchers design re-engineered hospital discharge program to reduce rehospitalization 2MinuteClinic Becomes Participating Provider With Preferred Blue Network of BlueCross BlueShield of South CarolinaPalomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008Rigel to Present at BIO CEO & Investor ConferenceATS Medical Announces Australian Regulatory Approval for ATS 3f Aortic BioprosthesisiCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT StudiesResearchers design re-engineered hospital discharge program to reduce rehospitalization
(Date:12/3/2009)...FORT WORTH, Texas, Dec. 3 /PRNewswire-FirstCall/...letin Board: WNDM), a rapidly growing provider of ...eement with the Health Industry Representative Ass...ndent sales and marketing representative to market...thin the U.S. ,, HIRA will market and sell Wou...
(Date:12/3/2009)...IEGO, Dec. 3 Cardium The...its wholly-owned subsidiary, Tissue Repair Company... with the U.S. Food and Drug Administration (FDA) ... product candidate based on positive data from th...nical study. Today,s submission with the FDA cove...
(Date:12/3/2009)...YORK, Dec. 3 Alzheimer,s disease (...erson can receive. This irreversible, progressive ...skills and eventually even the ability to carry ou...entia among older people, AD affects as many as 2....he National Institute on Aging. ,, (Logo: ht...
Breaking Medicine Technology:Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Alzheimer's Research May Lead to Preventing the Debilitating Disease 2Alzheimer's Research May Lead to Preventing the Debilitating Disease 3Recovery act funded research projects aid communities across the country 9428 1Learning Takes Place When You Get Things Right 53240 1Learning Takes Place When You Get Things Right 53240 2State Report Ranks LIJ as New Yorks Best for Heart Bypass Surgery North Shore University Hospital Tops for Emergency Angioplasty Survival 53235 1State Report Ranks LIJ as New Yorks Best for Heart Bypass Surgery North Shore University Hospital Tops for Emergency Angioplasty Survival 53235 2[0] Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up[0] Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds[0] Alzheimer's Research May Lead to Preventing the Debilitating Disease
...ers are testing 92 medicines and vaccines to treat...ding to a report released today by,the Pharmaceuti... December,1 marks the 20th anniversary of "World A...nated at the 1988 World Summit of Ministers of Hea...reatly encouraged by the new, critically-important...
.... (Eurolist:,COX) today announced that TOPIGEN Pha...a phase 2 proof of concept study for TPI 1020 in C...TOPIGEN press release attached.,This new study is ...20,s,potential activity in COPD. TPI 1020 is a new...nsed by TOPIGEN from NicOx for COPD and other,resp...
Other Medicine Technology:92 Medicines and Vaccines now in Development for HIV/AIDS 292 Medicines and Vaccines now in Development for HIV/AIDS 3NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 2NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 3NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 4NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 5NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 6NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020 7| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |